Clinical trial
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
NCT00455052 · Mersana Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00455052 |
|---|---|
| Title | A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors |
| Official title | A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors |
| Lead sponsor | Mersana Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer, Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | XMT-1001 |
| Enrollment | 30 |
| Start date | Mar 1, 2011 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Apr 3, 2007 |
| Last update posted | Jan 31, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: